Our Pipeline

Gandeeva’s proprietary platform leverages artificial intelligence, machine learning, and high-resolution molecular imaging to enable our team to predict and drug transient protein-protein interactions for therapeutic benefit. Our strategy allows us to discover drugs against previously inaccessible targets in oncology with unmet medical needs.

Discovery & Optimization

IND-Enabling

Phase 1/2

GND-323

MAPK pathway

Development candidate selected

Discovery

IND-Enabling

Phase 1/2

GND-02

Gain-of-function iGlue™

Lead optimization ongoing

Discovery

IND-Enabling

Phase 1/2

GND-03

Inhibitory iGlue™

Hit validation ongoing

Discovery

IND-Enabling

Phase 1/2

GND-04

iGlue™

Target validation ongoing

Discovery

IND-Enabling

Phase 1/2

Partnering